Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
- University of Oslo
- Nanyang Technological University
- National University of Singapore
- City of Hope
- Harvard University
- Nature Careers
- UCL;
- University of New South Wales
- University of Nottingham
- University of Sydney
- MOHAMMED VI POLYTECHNIC UNIVERSITY
- RMIT University
- The Francis Crick Institute;
- UiT The Arctic University of Norway
- Villanova University
- Aarhus University
- AbbVie
- Amgen
- Auburn University
- CSIRO
- Centre for Genomic Regulation
- Centre for Genomic Regulation (CRG)
- DAAD
- FLINDERS UNIVERSITY
- Flinders University
- King's College London
- Max Planck Institute for Heart and Lung Research, Bad Nauheim
- Monash University
- Northeastern University
- OsloMet
- RMIT UNIVERSITY
- SINGAPORE INSTITUTE OF TECHNOLOGY (SIT)
- The University of Queensland
- UNIVERSITY OF THE SUNSHINE COAST - UNISC
- University of Colorado
- University of Leicester
- University of Lund
- University of Utah
- Université Gustave Eiffel
- Vanderbilt University
- Zukunftskolleg, University of Konstanz
- 31 more »
- « less
-
Field
-
Introduction: The PATHS study is a Ministry of Education (MOE)-funded longitudinal investigation tracking 500–600 Primary 1 students enrolled in the Learning Support Programme (LSP) and/or Learning Support for
-
. The key objectives are to support efforts to elucidating the molecular basis of type-2 diabetes, metabolic syndrome, including fatty liver disease and to track changes in inflammatory signatures and states
-
and synthesize target compounds. Conduct laboratory experiments for the synthesis of target compounds, including purification and characterization using techniques such as NMR, MS, FTIR, GC and HPLC
-
translational environment of the UCL Institute of Neurology, the ARUK UDDI is uniquely placed to find novel targets, rapidly validate identified novel targets and mechanisms, establish screens and progress
-
carcinogens in lung cancer initiation. We aspire to identify actionable targets within these pathways suitable for therapeutic intervention to prevent the onset of cancer. What you will be doing You will: Work
-
and Pharmacology). The Division has a track record in high-quality research across a broad range of drug discovery, pharmacy and patient safety-related areas, and for developing spinout companies
-
and Pharmacology). The Division has a track record in high-quality research across a broad range of drug discovery, pharmacy and patient safety-related areas, and for developing spinout companies
-
, scalable and cost-effective vaccine manufacturing—capability that may be applicable to other challenging vaccine targets. Your high-level duties will include: Under the direction of senior research
-
and in vivo studies—to identify novel therapeutic targets for inflammatory vascular diseases. Established in 2009, CICS is dedicated to accelerating the translation of basic cardiovascular research
-
Fellow - Health Economist (Level C) will work in partnership with other economists, clinical researchers and social scientists to evaluate public health interventions targeting a range of infectious